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Abstract
OBJECTIVE - To describe the long-term metabolic outcome of children with
congenital hyperinsulinism after near-total or partial elective pancreatectomy.
RESEARCH DESIGN AND METHODS - Patients (n = 105: 58 diffuse and
47 focal congenital hyperinsulinism) received operations between 1984 and
2006. Follow-up consisted of periodic measurements of pre- and postprandial
plasma glucose over 24 h,OGTT, and IVGTT. Cumulative incidence of hypo-
or hyperglycemia/insulin treatment was estimated by Kaplan- Meier analysis.
RESULTS - After near-total pancreatectomy, 59% of children with diffuse
congenital hyperinsulinism still presented mild or asymptomatic hypoglycemia
that responded to medical treatments and disappeared within 5 years. One-
third of the patients had both preprandial hypoglycemia and postprandial
hyperglycemia. Hyperglycemia was found in 53% of the patients immediately after
surgery; its incidence increased regularly to 100% at 13 years. The cumulative
incidence of insulin-treated ...
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OBJECTIVEdTo describe the long-term metabolic outcome of children with congenital hy-
perinsulinism after near-total or partial elective pancreatectomy.
RESEARCH DESIGN AND METHODSdPatients (n = 105: 58 diffuse and 47 focal
congenital hyperinsulinism) received operations between 1984 and 2006. Follow-up consisted
of periodicmeasurements of pre- and postprandial plasma glucose over 24 h, OGTT, and IVGTT.
Cumulative incidence of hypo- or hyperglycemia/insulin treatment was estimated by Kaplan-
Meier analysis.
RESULTSdAfter near-total pancreatectomy, 59% of children with diffuse congenital hyper-
insulinism still presented mild or asymptomatic hypoglycemia that responded to medical treat-
ments and disappeared within 5 years. One-third of the patients had both preprandial
hypoglycemia and postprandial hyperglycemia. Hyperglycemia was found in 53% of the patients
immediately after surgery; its incidence increased regularly to 100% at 13 years. The cumulative
incidence of insulin-treated patients was 42% at 8 years and reached 91% at 14 years, but the
progression to insulin dependence was very variable among the patients. Plasma insulin respon-
ses to IVGTT and OGTT correlated well with glycemic alterations. In focal congenital hyperin-
sulinism, hypoglycemia or hyperglycemia were rare, mild, and transient.
CONCLUSIONSdPatients with focal congenital hyperinsulinism are cured of hypoglycemia
after limited surgery, while the outcome of diffuse congenital hyperinsulinism is very variable
after near-total pancreatectomy. The incidence of insulin-dependent diabetes is very high in early
adolescence.
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Congenital hyperinsulinism is themost common cause of persistentsevere hypoglycemia at birth or in
early infancy, requiring early intensive
multidisciplinary management to pre-
vent brain damage (1,2). The inappro-
priate secretion of insulin by the b-cells
has heterogeneous genetic origins. In
the neonatal forms of congenital hyper-
insulinism, the most common genetic
mutations (in ABCC8 and KCNJ11
genes) cause alterations of the ATP-
dependent K+ channels (SUR1 and Kir6.2
subunits) in the b-cells, which play a
critical role in the regulation of insulin
secretion (3).
The frequent resistance of congenital
hyperinsulinism to medical treatments of-
ten leads to surgery, which has for a long
time consisted of near-total pancreatec-
tomy,with a high risk of insulin-dependent
diabetes (4–7). However, the differentia-
tion between two formsdthe diffuse
form with no histological anomalies but
signs of b-cell hyperfunction and the ade-
nomatous localized hyperplasiadhas con-
siderably changed the surgical treatment
and the prognosis of the disease (8,9).
The focal forms can indeed be deﬁnitively
cured of hypoglycemia with partial elective
pancreatectomy (10). The preoperative dis-
tinction between the two formswas initially
established using selective pancreatic ve-
nous catherization (11,12), which has re-
cently been abandoned for the less invasive
positron emission tomography with [18F]
ﬂuoro-L-DOPA (13).
The long-term outcome of patients
suffering from congenital hyperinsulin-
ism has not been well described (4,5,14–
17). Few studies have clearly differentiated
diffuse and focal forms of insulin hyperse-
cretion. If the incidence of postoperative
recurrent hypoglycemia was often docu-
mented, the follow-up was often short
and data upon glucose tolerance and insu-
lin secretion were rarely available, making
it difﬁcult to evaluate the incidence of post-
surgical diabetes, although the risk seems
to be high before the second decade of life
after near-total pancreatectomy (4,5,16).
We report the long-term follow-up
study of glucose and insulin metabo-
lism in 105 children who underwent sur-
gery for either a focal or a diffuse form of
congenital hyperinsulinism. The study
clearly conﬁrms the contrast between the
evolution of the two forms but also shows
the great variability in the incidence of
hypoglycemia and hyperglycemia within
the diffuse form and contributes to char-
acterizing insulin secretion and sensitivity
and to determining the investigations
needed for an optimal follow-up.
RESEARCH DESIGN AND
METHODSdFrom 1984 to 2006, 105
patients received operations for congenital
hyperinsulinism atHôpital Necker–Enfants
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Malades and were followed over the long
term (Table 1). The ﬁrst symptoms oc-
curred in 87 neonates (,1 week), and af-
ter 1 month (to 1 year) of age in 18 cases.
The patients presented with severe (,0.3
mmol/L) pre- and postprandial hypoglyce-
mias, with no ketones, concomitant with
relatively high plasma insulin levels (.3
mU/L) and a glycemic response to subcu-
taneous glucagon. Syndromic or hyper-
ammonemic hyperinsulinisms and atypical
histological forms of hyperinsulinism
were not included in the study. In most
patients, the distinction between diffuse
and focal hyperinsulinism was based on
transhepatic portal catheterization (11,15)
or on results of a positron emission tomo-
graphy scan with [18F]ﬂuoro-L-DOPA (13).
Surgery was indicated in all patients
with a focal formand in thosewith adiffused
form of congenital hyperinsulinism that
resisted medical treatments where resection
was always identical. For the children who
required a second surgery (persistent hypo-
glycemia), the evaluation of follow-up star-
ted from the second intervention.
During surgery, biopsies were taken
in various areas of the pancreas and an-
alyzed extemporaneously to conﬁrm the
form, localize the focal lesion, and de-
termine the extent of the pancreatectomy
(8,18,19). For focal lesions, surgery was
limited to the head of the pancreas in 13
patients, the body in 6, and the tail in 5;
the head and body of the pancreas in 4
patients, the head and tail in 4, and the
body and tail in 4; and two-thirds of the
pancreas in 3 (not speciﬁed in 3 cases).
If a sample was taken, pancreatic
DNA was extracted to search for the spe-
ciﬁc loss of allele in the 11p15 region in
the focal lesion. When samples were avail-
able, mutations of the ABCC8, KCNJ11,
and the glucokinase genes were searched
for on blood leukocytes of the patients
and their parents, using PCR and direct
sequencing (Table 1).
Glucose metabolism and insulin se-
cretion were evaluated immediately after
surgery and then periodically for a mean
duration of 6.3 6 2.1 years (range 1–19)
in the diffuse forms and 2.6 6 4.1 years
(0–17) in the focal forms. The following
tests were used: HbA1c, plasma glucose,
insulin and C-peptide concentrations
over 24 h (before and after each meal
and at 0 and 4 h; 168 24-h cycles in 49
children with diffuse and 67 cycles in 39
children with focal congenital hyperinsu-
linism), oral glucose tolerance test
(OGTT) (77 tests in 23 children with dif-
fuse and 50 in 27 children with focal con-
genital hyperinsulinism), and intravenous
glucose tolerance test (IVGTT) (41 tests in
15 children with diffuse and 21 in 11 chil-
dren with focal congenital hyperinsulin-
ism). Hypoglycemia was deﬁned as a
value ,3 mmol/L during the 24-h cycle
(1). Hyperglycemia was deﬁned as an ab-
normalOGTT (WorldHealthOrganization
criteria), a plasma glucose level.11mmol/L
during the 24-h cycle, or HbA1c.6%. In-
sulin treatment was generally initiated
based on twomain criteria: permanent hy-
perglycemia (pre- and postprandial) and
elevated HbA1c (.7%). Plasma glucose
was measured by a glucose oxidase tech-
nique and plasma insulin by radioim-
munoassay (Bi-Insulin IRMA Ciis-Bio
International; Gif-sur-Yvette, France).
HbA1c was determined by high-pressure
liquid chromatography (Tosoh Bioscience
A1C 2.2) (National Glycohemoglobin
Standardization Program: normal values
4.2–5.6%).
Insulin secretion indices were com-
puted as the ratios of area under the curve
(AUC)insulin to AUCglucose and of
Dinsulin30–0 min to glucose30 min during
OGTT and as the sum of insulin levels at
19 and 39 during IVGTT (20). Insulin sen-
sitivity was assessed by the composite in-
sulin sensitivity index (21). Homeostasis
model assessment (HOMA) indices of
b-cell function and insulin sensitivity
were computed from baseline fasting lev-
els of glucose and insulin and expressed
as percentage of average values found in
young ﬁt subjects (22).
Statistical analysis
Data are given asmeans6 SD unless other-
wise indicated. The evolution of hypogly-
cemia and hyperglycemia or initiation of
insulin treatment was estimated using
Kaplan–Meier analysis. Given the small var-
iations in the ageof surgery, itwas considered
more appropriate to present these results in
relation to age rather than time after surgery.
Average values of glycemic control,
glucose tolerance, insulin secretion, and
insulin sensitivity throughout the follow-
up were compared between children with
focal or diffuse forms of congenital hy-
perinsulinism. To take into account that a
different number of tests was performed
in different individuals and in order to use
all the available data to maximize results,
we compared data between groups as
standard least squares computed in mixed
regression models with random effects,
including as covariables sex, the duration
of follow-up when the parameter was
measured, and the subject identiﬁcation
number. Statistics were performed with




Among 47 children who underwent oper-
ations for focal congenital hyperinsulinism,
none received any antidiabetes treatment.
Four children presented persisting but
asymptomatic hypoglycemias (three neo-
natal and one infant form) during the 24-h
cycles immediately after surgery. In only
one case, asymptomatic hypoglycemias
were also found at the age of 4 years, but
this patient showed no abnormalities at 3
or 5 years of age.
As for hyperglycemia, minor and
transitory anomalies were found. A child
Table 1dCharacteristics of 105 children who underwent near-total or partial elective
pancreatectomy for congenital hyperinsulinism
Neonates Infants
Diffuse Focal Diffuse Focal
Patients 52 35 6 12
Boys/girls 22/30 10/15 2/4 0/12
Term (weeks) 37.2 6 2.5 39.4 6 1.2 37.5 6 0.4 39.5 6 1.4
Birth weight (kg) 3.9 6 0.8 3.7 6 0.7 3.8 6 0.8 3.5 6 0.4
Age at surgery (years) 0.5 6 0.7 0.3 6 0.5 1.2 6 1.1 0.7 6 0.5
Second operation 10 1 0 1
Delay second operation (years) 0.3 6 0.3 1.9 d 0.5
Genetic study* 32 20 1 6
ABCC8 mutation 27 20 1 5
KCNJ11 mutation 2 0 0 1
Data are either mean 6 SD for the quantitative data or the n (of operation, patient, or mutation). *Genetic
study could not be performed in 20 neonates with diffuse congenital hyperinsulinism or in 15 with focal
congenital hyperinsulinism.
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had a plasma glucose of 8.8 mmol/L at
120 min of the OGTT at age 4 years, but
the OGTTwas normal at age 6 years. Four
children showed plasma glucose values
between 11.5 and 14.4 mmol/L at 30 or
60 min of OGTTs postoperatively and at
2, 4, and 10 years of age, but they showed
normal 24-h glucose cycles and no ab-
normalities at all other ages. In these ﬁve
patients, HbA1c remained in normal range
for the whole duration of the follow-up.
Diffuse hyperinsulinism
Of 58 children who underwent near-total
pancreatectomy for diffuse congenital hy-
perinsulinism, 59% were still suffering
from hypoglycemias immediately after
surgery (after ﬁrst surgery, 48 children;
after second surgery, 10 children). How-
ever, hypoglycemias did not have the
severity of those before surgery and they
occurred principally in the preprandial
periods, especially at the end of the night.
They could be controlled by dietetic ad-
justments (raw corn starch at bedtime in
16 children) and medical treatments
(in 15 patients: diazoxide in 10, octreotide
in 6, oral steroids in 11, and nifedipine in
2 and diazoxide-octreotide, diazoxide-
steroids, octreotide-steroids, or diazoxide-
nifedipine in 2–3 patients each). The
incidence of hypoglycemia decreased
slowly, in some cases persisting until
5 years of age (Fig. 1).
A very peculiar and unusual situation
was observed in 19 patients who pre-
sented fasting persisting hypoglycemia
(value ,3 mmol/L on the 24-h cycle) as-
sociated with postprandial hyperglycemia
(.11 mmol/L on the 24-h cycle or im-
paired glucose tolerance or diabetes at
the OGTT). This association, in 35% of
the children after surgery, could persist
until 5 years of age (Fig. 1).
One-half of the patients (53%) with
diffuse congenital hyperinsulinism pre-
sented with hyperglycemia in the days
after surgery. The incidence of hypergly-
cemia increased regularly with age, reach-
ing 100% at the age of 13 years (Fig. 1).
The incidence of insulin therapy in-
creased from 19% postoperatively to
42% at 8 years and then more rapidly to
reach 91% at 14 years of age. However, it
does not depict the great variability of the
postoperative progression toward deﬁni-
tive need for insulin in the 33 treated pa-
tients. Insulin therapy was started
immediately after surgery and deﬁnitively
(follow-up 5.4 6 3.8 years [range 0.5–
11]) in eight children. It was initiated
after a delay, between 5 months after sur-
gery and 14.8 years of age (age 8.46 4.2
years), and deﬁnitively in 13 patients
(Fig. 2). For the last 12 patients, the evolu-
tion was more erratic. Five patients re-
quired insulin immediately after surgery
but for a short period of time (1–16 days);
four of these ﬁve children remained hy-
perglycemic but untreated (follow-up
5.5 6 4.1 years [1–11]), while the last
one did not show any abnormality in glu-
cose tolerance up to 6 years of age. Four
patients received insulin immediately
after surgery for a longer period of time,
2–21 months (Fig. 2), but it had to be in-
terrupted for recurrent hypoglycemia; the
ﬁrst three remained hyperglycemic but
untreated until 1–3 years of age, while
the fourth again received insulin when 9
years old. For the last three patients, insu-
lin was started several months after sur-
gery, but it had to be stopped after 8–11
months for recurrent hypoglycemia; one
child remained untreated until 7.9 years of
age, while two were again treated with in-
sulin before 6 years of age.
Insulin secretion and sensitivity
In the fasting state, plasma insulin was
signiﬁcantly higher in the diffuse than in
the focal forms, and this was associated
with slightly lower plasma glucose values.
By contrast, all indices of glucose-stimulated
insulin secretion were signiﬁcantly lower,
which was associated with postprandial
(or postglucose) hyperglycemia in the dif-
fuse forms. Indices of insulin sensitivity did
not differ between the two forms (Table 2).
Metabolic follow-up after near-total
pancreatectomy
Comparisons were made between results
of the OGTT, the 24-h glucose cycle, and
HbA1c in the evaluation of the metabolic
status in diffuse hyperinsulinism, when at
least two tests were performed on the
same day: 72 pairs with OGTT and
HbA1c, 95 with the 24-h cycle and
HbA1c, and 56 with OGTT and the 24-h
cycle. When the OGTT was normal, the
other tests were also normal inmost cases.
When the OGTT showed criteria of dia-
betes, hyperglycemia was also found dur-
ing the 24-h cycle in 81% of the patients
and an HbA1c .5.6% in 58% of the pa-
tients. With criteria of impaired glucose
tolerance at the OGTT, hyperglycemia
was found in 18% and an HbA1c .5.6%
in 36% of the patients. When the 24-h
cycle showed hyperglycemia, HbA1c was
.5.6% in 56% of the patients. Relative to
that of the OGTT, the sensitivity of the
24-h glucose cycle was greater than that of
HbA1c (81 vs. 58%, respectively) for dia-
betes criteria, but it was very lowwith both
tests (18 and 36%) for impaired glucose
tolerance. The speciﬁcity varied from
69% (HbA1c) to 80% (24-h cycle) for di-
abetes and from 79 to 75% for impaired
glucose tolerance.
CONCLUSIONSdThe aim of this
work was to extend the description of the
metabolic evolution of patients who were
pancreatectomized for congenital hyper-
insulinism. We previously reported the
general evolution of 52 neonatal forms
of congenital hyperinsulinism after near-
total or partial elective pancreatectomy (15).
The greater number of patients followed
for a longer period of time after surgical
treatment based on well-identiﬁed lesions
makes these updated results of interest.
The present results illustrate the dra-
matic contrast in metabolic outcome
between the two forms of congenital
hyperinsulinism. The follow-up of 47
focal forms of hyperinsulinism strongly
conﬁrms that the childrenwho underwent
partial elective pancreatectomy were
cured of hypoglycemia. Our previous
results and those of other teams led to a
2000 European consensus on the man-
agement of persistent congenital hyper-
insulinism, which recommended a
conservative surgical attitude in the focal
forms (1). The development of the posi-
tron emission tomography scan with
[18F]ﬂuoro-L-DOPA (23), a less invasive
alternative to the transhepatic pancreatic
catheterization, should help to generalize
these recommendations and prevent pa-
tients from undergoing an unnecessary
extended pancreatectomy leading to a
progression toward insulin-dependent
Figure 1dCumulative incidence of hypoglyce-
mia (-), hyperglycemia (○), association hy-
pohyperglycemia (◇), and insulin therapy (C)
in 58 patients pancreatectomized for diffuse
congenital hyperinsulinism. Patients with both
hypo- and hyperglycemia are a subset of both
hypo- and hyperglycemia groups. yr, years.
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diabetes. However, one must keep in
mind that the existence of rare multifocal
and complex focal forms (23) of hyperin-
sulinism justiﬁes the systematic and regu-
lar evaluation of the surgery-treated
patients until complete disappearance of
hypoglycemia. Even in the present series,
two patients required a second surgery be-
cause all the hypersecreting hyperplasia
had not been resected. In contrast, al-
though the rare and mild hyperglycemia
observed during follow-up in some pa-
tients did not show any predictive value
of later deterioration of the metabolic sta-
tus, the ablation of a limited but signiﬁcant
part of the pancreas could add to later ag-
gravating factors, such as pregnancy, obe-
sity, or aging, and confer on these
subjects a risk of developing long-term
anomalies in glucose tolerance. A regular
and long-term follow-up, with periodic
evaluation of glucose tolerance, is thus
strongly recommended for these patients.
For the 58 operated diffuse forms, the
cumulative incidence of hyperglycemia
was 100% at 13 years of age and the
incidence of insulin therapy reached
91% a year later. As opposed to this in-
evitable evolution, the very slow progres-
sion toward insulin-requiring diabetes
is astonishing, such as the case of one
19-year-old patient, whowas free of insulin
with normal HbA1c and OGTT after a 95%
pancreatectomy in the ﬁrst months of life.
Indeed, this study clearly shows that post-
operative evolution is unpredictable and
sometimes complex, with a recurrence of
both hypo- and hyperglycemia. The age at
institution of insulin also varied greatly.
These characteristics are noteworthy, as
they may seem unexpected in view of the
extent of the pancreatic resection, but also
unusual compared with what is known of
the development of any other type of dia-
betes. However, whatever the variability of
this evolution, the ﬁnal result is insulin
therapy that was started before puberty in
more than one-half of the cases. These re-
sults thus conﬁrm previous reports in the
literature, with 33–40% of recurrent hypo-
glycemia risk, and the risk of being treated
with insulin was estimated to be between
14 and 69% in studies enrolling enough
patients to appreciate the incidence of this
complication (4,5,16). However, they
allow a nice detailed description of this evo-
lution based on a clear deﬁnition of the
histological form of the disease.
Such unpredictable evolution toward
diabetes seems to reﬂect the persistent
abnormal function of the pancreatic
residual tissue and, indeed, renders even
more complex the postoperative meta-
bolic evaluation of the patients. Pancreatic
endocrine function of these patients, using
metabolic tests, has previously been eval-
uated in one study, showing the altered
but variable insulin response to an IVGTT
and its poor correlation with later evolu-
tion (24). Results in our patients illustrate
that in some cases, the dramatic reduction
of b-cell mass cannot compensate for the
excessive insulin secretion of the remain-
ing cells. Remarkably, dysfunction of the
residual pancreatic tissue associates in
most cases an excessive fasting secretion
as a sequel of the b-cells dysfunction and
an expected lower insulin secretory capac-
ity in response to glucose as a sequel of the
extended resection. This clearly explains
the very novel association of fasting hypo-
glycemia and postprandial hyperglycemia
observed in a number of these patients in
the early years after surgery.
Mechanisms of progression toward
diabetes cannot be deﬁnitely stated from
this study. Some authors have suggested
that mutation of the ATP-dependent K+
channels could increase b-cell apoptosis
(25). However, the few data available
report a lower incidence of diabetes in
adulthood in diffuse congenital hyperin-
sulinism medically treated than that re-
ported here. If involution of the b-cells
in the remaining tissue of the patients
could contribute to the progressive de-
cline of insulin secretion and the develop-
ment of diabetes, the removal of 95% of
the pancreas is the most probable cause of
developing diabetes.
These results also have implications
for the various tests used to follow the
patients (1). The 24-h glucose cycle is
necessary to screen for hypoglycemia
and must thus be used in all focal and
diffuse forms as long as there is no cer-
tainty that there is no more risk of hypo-
glycemia. This is generally the case during
the ﬁrst months in the focal formsdthe
time to make sure that there is not a rare
complex or multifocal form. This can last
up to 5 years in the diffuse forms at an
annual or biannual rate. For hyperglyce-
mia, the OGTT remains themost sensitive
test to detect early impairment of glucose
tolerance and should be done every year
starting the year after surgery. During
OGTT, plasma insulin and glucose mea-
surements at 30 and 60 min of the OGTT
are not informative and can be omitted, as
they have shown little impact for the de-
tection of impaired glucose tolerance.
Figure 2dIllustration of changes over time of insulin requirements in 20 of the 33 patients
pancreatectomized for diffuse congenital hyperinsulinism. Four upper bars: Patients with insulin
immediately after surgery but transiently. The three following bars: Patients with insulin after
a delay but transiently. Thirteen lower bars: Patients with insulin after a delay and deﬁnitively.
The other patients are not presented: eight with insulin immediately after surgery and deﬁnitively,
with no insulin treatment (including ﬁve who received insulin immediately after surgery for 1–16
days). Dark bars, time of insulin therapy; gray bars, time of follow-up, with hyperglycemia but
without insulin. yr, years.
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IVGTT is not recommended during the
follow-up, as it does not provide any per-
tinent supplemental information. HbA1c
is of less interest for screening but be-
comes important when the patients reach
the state of diabetes for the decision to
start insulin therapy.
In conclusion, hypoglycemia due to
focal forms of congenital hyperinsulinism
is cured after partial elective pancreatec-
tomy, but the dramatic outcome of the
diffuse forms illustrates the urgent need
for progress in medical treatment to re-
duce the surgical indications and prevent
these patients from a high risk of insulin-
dependent diabetes in childhood and
adolescence.
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